| SEC For | -m 4 | | | | | | | | | | | | | | | | | |
|--|---|--|---|--|---|--|-------|---|---------------|--|---|--|--|--|-------------------------------|--|--|--|
| | FORM | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | | | | OMB APPROVAL | | | |
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | | | | Filed pu | ursuan | t to Section | n 16(| ES IN BI a) of the Sect | urities E | Exchan | _ | Estima | | | r: erage burden sponse: | 3235-0287 0.5 | | |
| 1. Name and Address of Reporting Person [*] Walker Neal | | | | | 2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
| (Last) (First) (Middle) C/O ACLARIS THERAPEUTICS, INC. | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024 | | | | | | | | X Officer (give title Other (specify below) Interim CEO | | | | pecify | |
| 701 LEE ROAD, SUITE 103 (Street) WAYNE PA | | | 19087 | 4. | . If Am | endment, [| Date | of Original Filed (Month/Day/Year) | | | Line | ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (S | itate) | ٦] | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | | |
| Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | ransactio | action 2A. Deemed Execution Date | | | a, 3. Transaction Dis Code (Instr. | | Desed of, or Benefic 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 | | ed (A) or | 5. Amoun | Form Form (D) or Following (I) (In | | : Direct Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | Code V | | mount | (A) or (D) | Price | Transacti (Instr. 3 a | ion(s) | | | instr. 4) | |
| | | | Table II - Der (e.g | | | | | uired, Dis s, options | | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable an Expiration Date (Month/Day/Year) | | and | 7. Title and of Securiti Underlying Derivative (Instr. 3 ar | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expir Date | | Title | Amount or Number of Shares | | (Instr. 4) | | | | |
| Stock Option (Right to Buy) | \$1.2 | 02/01/2024 | | A | | 497,000 | | (1) | 01/31 | 1/2034 | Common Stock | 497,000 | \$0.00 | 497,000 | | D | | |
| Restricted Stock Units | (2) | 02/01/2024 | | A | | 142,000 | | (1) | 0 | (1) | Common Stock | 142,000 | \$0.00 | 142,0 | 00 | D | | |

Explanation of Responses:

1. The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO.

2. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact 02/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.